Ebola virus

From Wikipedia, the free encyclopedia
Jump to: navigation, search
For the genus, see Ebolavirus. For other uses, see Ebola.
Ebola virus (EBOV)
Ebola virus em.png
Virus classification
Group: Group V ((-)ssRNA)
Order: Mononegavirales
Family: Filoviridae
Genus: Ebolavirus
Species: Zaire ebolavirus

Ebola virus (EBOV, formerly designated Zaire ebolavirus) is one of five known viruses within the genus Ebolavirus.[1] Four of the five known ebolaviruses, including EBOV, cause a severe and often fatal hemorrhagic fever in humans and other mammals, known as Ebola virus disease (EVD). Ebola virus has caused the majority of human deaths from EVD, and is the cause of the 2013–2014 Ebola virus epidemic in West Africa, which has resulted in at least 19,374 suspected cases and 7,533 confirmed deaths.[2][3][4]

Ebola virus and its genus were both originally named for Zaire (now the Democratic Republic of Congo), the country where it was first described,[1] and was at first suspected to be a new "strain" of the closely related Marburg virus.[5][6] The virus was renamed "Ebola virus" in 2010 to avoid confusion. Ebola virus is the single member of the species Zaire ebolavirus, which is the type species for the genus Ebolavirus, family Filoviridae, order Mononegavirales.[1][7] The natural reservoir of Ebola virus is believed to be bats, particularly fruit bats, and it is primarily transmitted between humans and from animals to humans through body fluids.[8]

The EBOV genome is a single-stranded RNA approximately 19,000 nucleotides long. It encodes seven structural proteins: nucleoprotein (NP), polymerase cofactor (VP35), (VP40), GP, transcription activator (VP30), VP24, and RNA-dependent RNA polymerase (L).[9]

Because of its high mortality rate, EBOV is also listed as a select agent, World Health Organization Risk Group 4 Pathogen (requiring Biosafety Level 4-equivalent containment), a U.S. National Institutes of Health/National Institute of Allergy and Infectious Diseases Category A Priority Pathogen, U.S. CDC Centers for Disease Control and Prevention Category A Bioterrorism Agent, and listed as a Biological Agent for Export Control by the Australia Group.

Structure[edit]

Phylogenetic tree comparing ebolaviruses and marburgviruses. Numbers indicate percent confidence of branches.

EBOV carries a negative-sense RNA genome in virions that are cylindrical/tubular, and contain viral envelope, matrix, and nucleocapsid components. The overall cylinders are generally approximately 80 nm in diameter, and have a virally encoded glycoprotein (GP) projecting as 7-10 nm long spikes from its lipid bilayer surface.[10] The cylinders are of variable length, typically 800 nm, but sometimes up to 1000 nm long. The outer viral envelope of the virion is derived by budding from domains of host cell membrane into which the GP spikes have been inserted during their biosynthesis.[citation needed] Individual GP molecules appear with spacings of about 10 nm.[citation needed] Viral proteins VP40 and VP24 are located between the envelope and the nucleocapsid (see following), in the matrix space.[11] At the center of the virion structure is the nucleocapsid, which is composed of a series of viral proteins attached to an 18–19 kb linear, negative-sense RNA without 3′-polyadenylation or 5′-capping (see following);[citation needed] the RNA is helically wound and complexed with the NP, VP35, VP30, and L proteins;[12][better source needed] this helix has a diameter of 80 nm and contains a central channel of 20–30 nm in diameter.

The overall shape of the virions after purification and visualization (e.g., by ultracentrifugation and electron microscopy, respectively) varies considerably; simple cylinders are far less prevalent than structures showing reversed direction, branches, and loops (e.g., U-, shepherd's crook-, 9- or eye bolt-shapes, or other or circular/coiled appearances), the origin of which may be in the laboratory techniques applied.[13] The characteristic "threadlike" structure is, however, a more general morphologic characteristic of filoviruses (alongside their GP-decorated viral envelope, RNA nucleocapsid, etc.).[13]

Genome[edit]

Each virion contains one molecule of linear, single-stranded, negative-sense RNA, 18,959 to 18,961 nucleotides in length. The 3′ terminus is not polyadenylated and the 5′ end is not capped. This viral genome codes for seven structural proteins and one non-structural protein. The gene order is 3′ – leader – NP – VP35 – VP40 – GP/sGP – VP30 – VP24 – L – trailer – 5′; with the leader and trailer being non-transcribed regions, which carry important signals to control transcription, replication, and packaging of the viral genomes into new virions. Sections of the NP, VP35 and the L genes from filoviruses have been identified as endogenous in the genomes of several groups of small mammals.[14][15][16]

It was found that 472 nucleotides from the 3' end and 731 nucleotides from the 5' end are sufficient for replication of a viral "minigenome", though not sufficient for infection.[13] The minigenome's genetic material by itself is not infectious, because viral proteins, among them the RNA-dependent RNA polymerase, are necessary to transcribe the viral genome into mRNAs because it is a negative sense RNA virus, as well as for replication of the viral genome.

Recent advances in genomic technologies have been applied to the analysis of blood samples from those infected in the 2014 outbreak. A massively parallel viral sequencing of genetic material collected from 78 patients with confirmed Ebola virus disease, representing more than 70% of cases diagnosed in Sierra Leone from late May to mid-June, 2014 was carried out.[17][18] This work provided near–real-time insights into the transmission dynamics and genetic evolution, shedding light on the origins of the virus causing the 2014 outbreak in West Africa, and whether the 2014 outbreak is still being fed by new contacts with its natural reservoir (no such evidence was found). As is typical of RNA-coded viruses,[17] the Ebola virus was found to mutate rapidly, both within a person during the progression of disease and in the reservoir among the local human population.[18] The observed mutation rate of 2.0 x 10-3 substitutions per site per year is as fast as that of seasonal influenza.[19] This is likely to represent rapid adaptation to human hosts as the virus is repeatedly passed from human to human (as opposed to usually being passed between fruit bats and only occasionally crossing over into humans), and may pose challenges for the development of a vaccine to the virus.[20][21]

Entry[edit]

There are two candidates for host cell entry proteins. The first is a cholesterol transporter protein, the host-encoded Niemann–Pick C1 (NPC1), which appears to be essential for entry of Ebola virions into the host cell and for its ultimate replication.[22][23] In one study, mice with one copy of the NPC1 gene removed showed an 80 percent survival rate fifteen days after exposure to mouse-adapted Ebola virus, while only 10 percent of unmodified mice survived this long.[jargon][22] In another study, small molecules were shown to inhibit Ebola virus infection by preventing viral envelope glycoprotein (GP) from binding to NPC1.[23][24] Hence, NPC1 was shown to be critical to entry of this filovirus, because it mediates infection by binding directly to viral GP.[23]

When cells from Niemann–Pick Type C patients lacking this transporter were exposed to Ebola virus in the laboratory, the cells survived and appeared impervious to the virus, further indicating that Ebola relies on NPC1 to enter cells;[22] mutations in the NPC1 gene in humans were conjectured as a possible mode to make some individuals resistant to this deadly viral disease.[citation needed][speculation?] The same studies described similar results regarding NPC1's role in virus entry for Marburg virus, a related filovirus.[22] A further study has also presented evidence that NPC1 is the critical receptor mediating Ebola infection via its direct binding to the viral GP, and that it is the second "lysosomal" domain of NPC1 that mediates this binding.[25]

The second candidate is TIM-1 (aka HAVCR1).[26] TIM-1 was shown to bind to the receptor binding domain of the EBOV glycoprotein, to increase the receptivity of Vero cells. Silencing its effect with siRNA prevented infection of Vero cells. TIM1 is expressed in tissues known to be seriously impacted by EBOV lysis (trachea, cornea, and conjunctiva). A monoclonal antibody against the IgV domain of TIM-1, ARD5, blocked EBOV binding and infection.

Together, these studies suggest NPC1 and TIM-1 may be potential therapeutic targets for an Ebola anti-viral drug and as a basis for a rapid field diagnostic assay.[citation needed]

Replication[edit]

Being acellular, viruses such as Ebola do not replicate through any type of cell division; rather, they use a combination of host- and virally encoded enzymes, alongside host cell structures, to produce multiple copies of themselves. These then self-assemble into viral macromolecular structures in the host cell.[12][better source needed] The virus completes a set of steps when infecting each individual cell:[citation needed]

The virus begins its attack by attaching to host receptors through the glycoprotein (GP) surface peplomer and is endocytosed into macropinosomes in the host cell.[27][non-primary source needed] To penetrate the cell, the viral membrane fuses with vesicle membrane, and the nucleocapsid is released into the cytoplasm. Encapsidated, negative-sense genomic ssRNA is used as a template for the synthesis (3'-5') of polyadenylated, monocistronic mRNAs and, using the host cell's ribosomes, tRNA molecules, etc., the mRNA is translated into individual viral proteins.

These viral proteins are processed: a glycoprotein precursor (GP0) is cleaved to GP1 and GP2, which are then heavily glycosylated using cellular enzymes and substrates. These two molecules assemble, first into heterodimers, and then into trimers to give the surface peplomers. Secreted glycoprotein (sGP) precursor is cleaved to sGP and delta peptide, both of which are released from the cell.[citation needed] As viral protein levels rise, a switch occurs from translation to replication. Using the negative-sense genomic RNA as a template, a complementary +ssRNA is synthesized; this is then used as a template for the synthesis of new genomic (-)ssRNA, which is rapidly encapsidated.

The newly formed nucleocapsids and envelope proteins associate at the host cell's plasma membrane; budding occurs, destroying the cell.

Ecology[edit]

Ebola virus is a zoonotic pathogen. Intermediary hosts have been reported to be "various species of fruit bats ... throughout central and sub-Saharan Africa". Evidence of infection in bats has been detected through molecular and serologic means. However, ebolaviruses have not been isolated in bats.[28] End hosts are humans and great apes, infected through bat contact or through other end hosts. Pigs on the Philippine islands have been reported to be infected with Reston virus, so other interim or amplifying hosts may exist.[28]

Ebola virus disease[edit]

Main article: Ebola virus disease

Ebola virus is one of the four ebolaviruses known to cause disease in humans. It has the highest case-fatality rate of these ebolaviruses, averaging 83 percent since the first outbreaks in 1976, although fatality rates up to 90 percent have been recorded in one epidemic (2002–03). There have also been more outbreaks of Ebola virus than of any other ebolavirus. The first outbreak occurred on 26 August 1976 in Yambuku.[29] The first recorded case was Mabalo Lokela, a 44‑year-old schoolteacher. The symptoms resembled malaria, and subsequent patients received quinine. Transmission has been attributed to reuse of unsterilized needles and close personal contact, body fluids and places where the person has touched.

During the 1976 Ebola outbreak in Zaire, Ngoy Mushola travelled from Bumba to Yambuku, where he recorded the first clinical description of the disease in his daily log:[30]

"The illness is characterized with a high temperature of about 39°C, hematemesis, diarrhea with blood, retrosternal abdominal pain, prostration with "heavy" articulations, and rapid evolution death after a mean of three days."

The severity of the disease in humans varies widely, from rapid fatality to mild illness or even asymptomatic response.[31] Studies of outbreaks in the late twentieth century failed to find a correlation between the disease severity and the genetic nature of the virus. Hence the variability in the severity of illness was suspected to correlate with genetic differences in the victims. This has been difficult to study in animal models that respond to the virus with hemorrhagic fever in a similar manner as humans, because typical mouse models do not so respond, and the required large numbers of appropriate test subjects are not easily available. In late October 2014, a publication reported a study of the response to a mouse-adapted strain of Zaire ebolavirus presented by a genetically diverse population of mice that was bred to have a range of responses to the virus that includes fatality from hemorrhagic fever.[32] It was found that the wide range of these rodents' responses to this single virus genotype mimics that of humans to the wild virus, suggesting that genetic differences among the victims is key. The much more detailed study of the response that is possible in an animal model is expected to result in the identification of genes that control the response to the virus.

History and nomenclature[edit]

Ebola virus (/ε'boʊlə vaɪrəs/)[1] was first identified as a possible new "strain" of Marburg virus in 1976.[5][6][33] At the same time, a third team introduced the name "Ebola virus", derived from the Ebola River where the 1976 outbreak occurred.[1][5][6][34] The International Committee on Taxonomy of Viruses (ICTV) identifies Ebola virus as species Zaire ebolavirus, which is included into the genus Ebolavirus, family Filoviridae, order Mononegavirales. The name "Ebola virus" is derived from the Ebola River—a river that was at first thought to be in close proximity to the area in Democratic Republic of Congo, previously called Zaire, where the 1976 Zaire Ebola virus outbreak occurred—and the taxonomic suffix virus.[1]

In 2000, the virus name was changed to Zaire Ebola virus,[35][36] and in 2002 to species Zaire ebolavirus.[37][38] However, most scientific articles continued to refer to "Ebola virus" or used the terms Ebola virus and Zaire ebolavirus in parallel. Consequently, in 2010, a group of researchers recommended that the name "Ebola virus" be adopted for a subclassification within the species Zaire ebolavirus, with the corresponding abbreviation EBOV.[1] Previous abbreviations for the virus were EBOV-Z (for Ebola virus Zaire) and ZEBOV (for Zaire Ebola virus or Zaire ebolavirus). In 2011, the ICTV explicitly rejected a proposal (2010.010bV) to recognize this name, as ICTV does not designate names for subtypes, variants, strains, or other subspecies level groupings.[39] At present, ICTV does not officially recognize "Ebola virus" as a taxonomic rank, and rather continues to use and recommend only the species designation Zaire ebolavirus.[40]

The prototype Ebola virus, variant Mayinga (EBOV/May), was named for Mayinga N'Seka, a nurse who died during the 1976 Zaire outbreak.[1][41][42]

Vaccine[edit]

Many Ebola vaccine candidates had been developed in the decade prior to 2014,[43] but as of October 2014, none had yet been approved by the United States Food and Drug Administration (FDA) for clinical use in humans.[44][45][46] Inactivated Ebola virus vaccines were shown to not promote an adequate immune response to the real pathogen. Several promising vaccine candidates that integrate viral subunits have been shown to protect nonhuman primates (usually macaques) against lethal infection.[47][48] These include replication-deficient adenovirus vectors, replication-competent vesicular stomatitis (VSV) and human parainfluenza (HPIV-3) vectors, and virus-like particle preparations. Conventional trials to study efficacy by exposure of humans to the pathogen after immunization are obviously not feasible in this case. For such situations, the FDA has established the “animal rule” allowing licensure to be approved on the basis of animal model studies that replicate human disease, combined with evidence of safety and a potentially potent immune response (antibodies in the blood) from humans given the vaccine. Phase I clinical trials involve the administration of the vaccine to healthy human subjects to evaluate the immune response, identify any side effects and determine the appropriate dosage. As of October, 2014, such trials had begun for the replication-deficient cAd3-EBO Z vaccine,[49] and for the replication-competent VSV-EBOV vaccine.[50][51][52][53][54]

Virus inclusion criteria[edit]

A virus of the species Zaire ebolavirus is an Ebola virus (EBOV) if it has the properties of Zaire ebolaviruses and if its genome diverges from that of the prototype Ebola virus, Ebola virus variant Mayinga (EBOV/May), by ten percent or less at the nucleotide level.[1]

Literature[edit]

Robin Cook's 1987 novel Outbreak

William Close's 1995 Ebola: A Documentary Novel of Its First Explosion and 2002 Ebola: Through the Eyes of the People focused on individuals' reactions to the 1976 Ebola outbreak in Zaire.[55]

Tom Clancy's 1996 novel, Executive Orders, involves a Middle Eastern terrorist attack on the United States using an airborne form of a deadly Ebola virus named "Ebola Mayinga".[56]

References[edit]

  1. ^ a b c d e f g h i Kuhn, Jens H.; Becker, Stephan; Ebihara, Hideki; Geisbert, Thomas W.; Johnson, Karl M.; Kawaoka, Yoshihiro; Lipkin, W. Ian; Negredo, Ana I et al. (2010). "Proposal for a revised taxonomy of the family Filoviridae: Classification, names of taxa and viruses, and virus abbreviations". Archives of Virology 155 (12): 2083–103. doi:10.1007/s00705-010-0814-x. PMC 3074192. PMID 21046175. 
  2. ^ "EBOLA RESPONSE ROADMAP SITUATION REPORT-17 DECEMBER 2014". World Health organization. 17 December 2014. Retrieved 18 December 2014. 
  3. ^ "Sierra Leone: EBOLA VIRUS DISEASE - SITUATION REPORT (Sit-Rep) 15 December, 2014". 15 December 2014. Retrieved 15 December 2014. 
  4. ^ "Liberia Ebola SitRep no. 213". 18 December 2014. Retrieved 18 December 2014. 
  5. ^ a b c Pattyn, S.; Jacob, W.; van der Groen, G.; Piot, P.; Courteille, G. (1977). "Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire". Lancet 309 (8011): 573–4. doi:10.1016/s0140-6736(77)92002-5. PMID 65663. 
  6. ^ a b c Bowen, E. T. W.; Lloyd, G.; Harris, W. J.; Platt, G. S.; Baskerville, A.; Vella, E. E. (1977). "Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent". Lancet 309 (8011): 571–3. doi:10.1016/s0140-6736(77)92001-3. PMID 65662. 
  7. ^ WHO. "Ebola virus disease". 
  8. ^ Angier, Natalie (October 27, 2014). "Killers in a Cell but on the Loose - Ebola and the Vast Viral Universe". New York Times. Retrieved October 27, 2014. 
  9. ^ Nanbo, Asuka; Watanabe, Shinji; Halfmann, Peter; Kawaoka, Yoshihiro (4 Feb 2013). "The spatio-temporal distribution dynamics of Ebola virus proteins and RNA in infected cells". Nature 3: 1206. Bibcode:2013NatSR...3E1206N. doi:10.1038/srep01206. 
  10. ^ Klenk & Feldmann 2004, p. 28.
  11. ^ Feldmann, H. K. (1993). "Molecular biology and evolution of filoviruses". Archives of virology. Supplementum 7: 81–100. ISSN 0939-1983. PMID 8219816.  edit
  12. ^ a b Biomarker Database. Ebola virus. Korea National Institute of Health. Retrieved 2009-05-31. 
  13. ^ a b c Klenk, H-D; Feldmann, H (editor) (2004). Ebola and Marburg Viruses: Molecular and Cellular Biology. Horizon Bioscience. ISBN 978-1-904933-49-6. 
  14. ^ Taylor, D.; Leach, R.; Bruenn, J. (2010). "Filoviruses are ancient and integrated into mammalian genomes". BMC Evolutionary Biology 10: 193. doi:10.1186/1471-2148-10-193. PMC 2906475. PMID 20569424.  edit
  15. ^ Belyi, V. A.; Levine, A. J.; Skalka, A. M. (2010). Buchmeier, Michael J., ed. "Unexpected Inheritance: Multiple Integrations of Ancient Bornavirus and Ebolavirus/Marburgvirus Sequences in Vertebrate Genomes". PLoS Pathogens 6 (7): e1001030. doi:10.1371/journal.ppat.1001030. PMC 2912400. PMID 20686665.  edit
  16. ^ Taylor, D. J.; Ballinger, M. J.; Zhan, J. J.; Hanzly, L. E.; Bruenn, J. A. (2014). "Evidence that ebolaviruses and cuevaviruses have been diverging from marburgviruses since the Miocene". PeerJ 2: e556. doi:10.7717/peerj.556.  edit
  17. ^ a b Richard Preston (27 October 2014). "The Ebola Wars". The NewYorker (New York: Condé Nast). Retrieved 20 October 2014. 
  18. ^ a b Stephen K. Gire with 57 others (2014). "Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak". Science 345 (6202): 1369–1372. doi:10.1126/science.1259657. 
  19. ^ Jenkins, G. M.; Rambaut, A; Pybus, O. G.; Holmes, E. C. (2002). "Rates of molecular evolution in RNA viruses: A quantitative phylogenetic analysis". Journal of Molecular Evolution 54 (2): 156–65. doi:10.1007/s00239-001-0064-3. PMID 11821909.  edit
  20. ^ Tracking a Serial Killer: Could Ebola Mutate to Become More Deadly? David Quammen, National Geographic News, 15 October 2014
  21. ^ Ebola 2014 is Mutating as Fast as Seasonal Flu. Operonlabs.com, 16 October 2014
  22. ^ a b c d Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Dal Cin P, Dye JM, Whelan SP, Chandran K, Brummelkamp TR; Raaben; Wong; Herbert; Obernosterer; Mulherkar; Kuehne; Kranzusch; Griffin; Ruthel; Dal Cin; Dye; Whelan; Chandran; Brummelkamp (September 2011). "Ebola virus entry requires the cholesterol transporter Niemann-Pick C1". Nature 477 (7364): 340–3. Bibcode:2011Natur.477..340C. doi:10.1038/nature10348. PMC 3175325. PMID 21866103. Lay summaryNew York Times. 
  23. ^ a b c Côté M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J; Misasi; Ren; Bruchez; Lee; Filone; Hensley; Li; Ory; Chandran; Cunningham (September 2011). "Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection". Nature 477 (7364): 344–8. Bibcode:2011Natur.477..344C. doi:10.1038/nature10380. PMC 3230319. PMID 21866101. Lay summaryNew York Times. 
  24. ^ Flemming A (October 2011). "Achilles heel of Ebola viral entry". Nat Rev Drug Discov 10 (10): 731. doi:10.1038/nrd3568. PMID 21959282. 
  25. ^ Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, Ndungo E, Sandesara RG, Carette JE, Kuehne AI, Ruthel G, Pfeffer SR, Dye JM, Whelan SP, Brummelkamp TR, Chandran K; Obernosterer; Raaben; Herbert; Deffieu; Krishnan; Ndungo; Sandesara; Carette; Kuehne; Ruthel; Pfeffer; Dye; Whelan; Brummelkamp; Chandran (March 2012). "Ebola virus entry requires the host-programmed recognition of an intracellular receptor". EMBO Journal 31 (8): 1947–60. doi:10.1038/emboj.2012.53. PMC 3343336. PMID 22395071. 
  26. ^ Kondratowicz AS, Lennemann NJ, Sinn PL et al. (May 2011). "T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus". Proceedings of the National Academy of Sciences of the United States of America 108 (20): 8426–31. doi:10.1073/pnas.1019030108. PMC 3100998. PMID 21536871. 
  27. ^ Saeed, M. F.; Kolokoltsov, A. A.; Albrecht, T.; Davey, R. A. (2010). Basler, Christopher F., ed. "Cellular Entry of Ebola Virus Involves Uptake by a Macropinocytosis-Like Mechanism and Subsequent Trafficking through Early and Late Endosomes". PLoS Pathogens 6 (9): e1001110. doi:10.1371/journal.ppat.1001110. PMC 2940741. PMID 20862315.  edit
  28. ^ a b Feldmann H (May 2014). "Ebola — A Growing Threat?". N. Engl. J. Med. 371 (15): 1375–8. doi:10.1056/NEJMp1405314. PMID 24805988. 
  29. ^ Isaacson, M; Sureau, P; Courteille, G; Pattyn, SR;. "Clinical Aspects of Ebola Virus Disease at the Ngaliema Hospital, Kinshasa, Zaire, 1976". Retrieved 2014-06-24. 
  30. ^ Bardi, Jason Socrates. "Death Called a River". The Scripps Research Institute. Retrieved 9 October 2014. 
  31. ^ Gina Kolata (Oct 30, 2014). "Genes Influence How Mice React to Ebola, Study Says in ‘Significant Advance’". New York Times. Retrieved Oct 30, 2014. 
  32. ^ Angela L. Rasmussen with 21 others (Oct 30, 2014). "Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance". Science. doi:10.1126/science.1259595. Retrieved Oct 30, 2014. 
  33. ^ http://www.bbc.com/news/magazine-28262541
  34. ^ Johnson, K. M.; Webb, P. A.; Lange, J. V.; Murphy, F. A. (1977). "Isolation and partial characterisation of a new virus causing haemorrhagic fever in Zambia". Lancet 309 (8011): 569–71. doi:10.1016/s0140-6736(77)92000-1. PMID 65661. 
  35. ^ Netesov, S. V.; Feldmann, H.; Jahrling, P. B.; Klenk, H. D.; Sanchez, A. (2000). "Family Filoviridae". In van Regenmortel, M. H. V.; Fauquet, C. M.; Bishop, D. H. L.; Carstens, E. B.; Estes, M. K.; Lemon, S. M.; Maniloff, J.; Mayo, M. A.; McGeoch, D. J.; Pringle, C. R.; Wickner, R. B. Virus Taxonomy—Seventh Report of the International Committee on Taxonomy of Viruses. San Diego, USA: Academic Press. pp. 539–48. ISBN 0-12-370200-3{{inconsistent citations}} 
  36. ^ Pringle, C. R. (1998). "Virus taxonomy-San Diego 1998". Archives of Virology 143 (7): 1449–59. doi:10.1007/s007050050389. PMID 9742051. 
  37. ^ Feldmann, H.; Geisbert, T. W.; Jahrling, P. B.; Klenk, H.-D.; Netesov, S. V.; Peters, C. J.; Sanchez, A.; Swanepoel, R.; Volchkov, V. E. (2005). "Family Filoviridae". In Fauquet, C. M.; Mayo, M. A.; Maniloff, J.; Desselberger, U.; Ball, L. A. Virus Taxonomy—Eighth Report of the International Committee on Taxonomy of Viruses. San Diego, USA: Elsevier/Academic Press. pp. 645–653. ISBN 0-12-370200-3. 
  38. ^ Mayo, M. A. (2002). "ICTV at the Paris ICV: results of the plenary session and the binomial ballot". Archives of Virology 147 (11): 2254–60. doi:10.1007/s007050200052. 
  39. ^ "Replace the species name Lake Victoria marburgvirus with Marburg marburgvirus in the genus Marburgvirus". 
  40. ^ International Committee on Taxonomy of Viruses. "Virus Taxonomy: 2013 Release". 
  41. ^ Wahl-Jensen, V.; Kurz, S. K.; Hazelton, P. R.; Schnittler, H.-J.; Stroher, U.; Burton, D. R.; Feldmann, H. (2005). "Role of Ebola Virus Secreted Glycoproteins and Virus-Like Particles in Activation of Human Macrophages". Journal of Virology 79 (4): 2413. doi:10.1128/JVI.79.4.2413-2419.2005. PMID 15681442. 
  42. ^ Kesel, A. J.; Huang, Z; Murray, M. G.; Prichard, M. N.; Caboni, L; Nevin, D. K.; Fayne, D; Lloyd, D. G.; Detorio, M. A.; Schinazi, R. F. (2014). "Retinazone inhibits certain blood-borne human viruses including Ebola virus Zaire". Antiviral Chemistry and Chemotherapy 23 (5): 197–215. doi:10.3851/IMP2568. PMID 23636868. 
  43. ^ Richardson JS, Dekker JD, Croyle MA, Kobinger GP (June 2010). "Recent advances in Ebolavirus vaccine development". Human Vaccines (open access) 6 (6): 439–49. doi:10.4161/hv.6.6.11097. PMID 20671437. 
  44. ^ "Statement on the WHO Consultation on potential Ebola therapies and vaccines". WHO. 5 September 2014. Retrieved 1 October 2014. 
  45. ^ "2014 Ebola Outbreak in West Africa". Retrieved Oct 2014. 
  46. ^ Alison P. Galvani with three others (21 August 2014). "Ebola Vaccination: If Not Now, When?". Annals of Internal Medicine. doi:10.7326/M14-1904. 
  47. ^ Hoenen T, Groseth A, Falzarano D, Feldmann H (May 2006). "Ebola virus: unravelling pathogenesis to combat a deadly disease". Trends in Molecular Medicine 12 (5): 206–215. doi:10.1016/j.molmed.2006.03.006. PMID 16616875. 
  48. ^ Hugues Fausther-Bovendo with two others (2012). "Ebolavirus vaccines for humans and apes". Current Opinion in Virology 2 (3): 324–329. doi:10.1016/j.coviro.2012.04.003. 
  49. ^ Vaccine Research Center, NIAID (29 September 2014). "Ebola Vaccine Clinical Development Overview (presentation)". Retrieved 21 October 2014. 
  50. ^ "Canadian-made Ebola vaccine to start clinical trials in healthy humans". Globe and Mail. 13 Oct 2014. Retrieved 13 October 2014. 
  51. ^ "Ebola outbreak: 1st human trials of Canadian vaccine start in U.S.". CBC News. 13 October 2014. 
  52. ^ "Canadian Ebola vaccine license holder moving ahead with safety trials". Canadian Press. 8 Oct 2014. Retrieved 13 October 2014. 
  53. ^ "A Phase 1 Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults". US NIAID. 9 Oct 2014. Retrieved 13 October 2014. 
  54. ^ Hannah Thibedeau (19 Oct 2014). "Ebola vaccine to be sent to WHO on Monday for clinical trials". CBC News. Retrieved 21 October 2014. 
  55. ^ (1) Close, William T. (1995). Ebola: A Documentary Novel of Its First Explosion. New York: Ivy Books. ISBN 0804114323. OCLC 32753758.  At Google Books.
    (2) Grove, Ryan (2006-06-02). "More about the people than the virus". Review of Close, William T., Ebola: A Documentary Novel of Its First Explosion. Amazon.com. Retrieved 2014-09-17. 
    (3) Close, William T. (2002). Ebola: Through the Eyes of the People. Marbleton, Wyoming: Meadowlark Springs Productions. ISBN 0970337116. OCLC 49193962.  At Google Books.
    (4) Pink, Brenda (2008-06-24). "A fascinating perspective". Review of Close, William T., Ebola: Through the Eyes of the People. Amazon.com. Retrieved 2014-09-17. 
  56. ^ (1) Clancy, Tom (1996). Executive Orders. New York: Putnam. ISBN 0399142185. OCLC 34878804.  At Google Books.
    (2) Line, Matt; Jeremy; Dan. "Executive Orders book reviews". AllReaders.com. Archived from the original on 2014-08-01. Retrieved 2014-09-10. 
    (3) Stone, Oliver (1996-09-02). "Who's That in the Oval Office?". Books News & Reviews. The New York Times Company. Archived from the original on 2009-04-10. Retrieved 2014-09-10. 

Citations

  • Klenk, Hans-Dieter; Feldmann, Heinz (2004). Ebola and Marburg Viruses – Molecular and Cellular Biology. Wymondham, Norfolk, UK: Horizon Bioscience. ISBN 978-0-9545232-3-7. 

External links[edit]